GSK

GSK plc is a global biopharma company that develops, manufactures, and markets pharmaceutical medicines, vaccines, and specialty medicines. Headquartered in Brentford, United Kingdom, the company operates through two primary business segments: Vaccines and Specialty Medicines. GSK's portfolio includes treatments for infectious diseases, HIV, oncology, and immunology, with key products including Shingrix (shingles vaccine), Nucala (severe asthma), Trelegy (COPD), and Blenrep (multiple myeloma). The company employs approximately 69,000 people worldwide and operates manufacturing facilities across more than 30 countries. In July 2022, GSK completed the demerger of its Consumer Healthcare division, which combined with Pfizer's consumer business to form Haleon plc, allowing GSK to focus exclusively on prescription medicines and vaccines. The company maintains one of the industry's largest vaccine portfolios, supplying approximately 2 million doses daily to people across more than 150 countries. GSK invests heavily in research and development, with particular focus on areas of immunology, infectious diseases, oncology, and genetics. The company's pipeline includes several late-stage candidates targeting respiratory diseases, HIV prevention, and various cancers. GSK generates annual revenues exceeding £29 billion and maintains significant presence in both developed and emerging markets, positioning itself as a leading specialized biopharma company.